| Dale Ando, MD |
| Chief Medical Officer and Vice President of Development, Sangamo BioSciences, Inc. |
| First-in-Man Gene Editing Using Zinc Finger Nucleases to Modify CCR5 in HIV Subject T Cells http://www.isbiotech.org/cellulartherapies |
| Dale Ando, MD |
| Chief Medical Officer and Vice President of Development, Sangamo BioSciences, Inc. |
| First-in-Man Gene Editing Using Zinc Finger Nucleases to Modify CCR5 in HIV Subject T Cells http://www.isbiotech.org/cellulartherapies |
No comments:
Post a Comment